At a glance
- Originator Nonindustrial source
- Class Antineoplastics; Small molecules
- Mechanism of Action
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Cancer
Most Recent Events
- 07 Apr 1999 Merger of Astra and Zeneca to form AstraZeneca completed
- 13 Nov 1998 Preclinical development for Cancer in Spain (Unknown route)